Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Originally published in Science Express on 19 May 2005
Science 17 June 2005:
Vol. 308. no. 5729, pp. 1777 - 1783
DOI: 10.1126/science.1112286
Prev | Table of Contents | Next

Reports

This article has been retracted

Patient-Specific Embryonic Stem Cells Derived from Human SCNT Blastocysts

Woo Suk Hwang,1,2* Sung Il Roh,3 Byeong Chun Lee,1 Sung Keun Kang,1 Dae Kee Kwon,1 Sue Kim,1 Sun Jong Kim,3 Sun Woo Park,1 Hee Sun Kwon,1 Chang Kyu Lee,2 Jung Bok Lee,3 Jin Mee Kim,3 Curie Ahn,4 Sun Ha Paek,4 Sang Sik Chang,5 Jung Jin Koo,5 Hyun Soo Yoon,6 Jung Hye Hwang,6 Youn Young Hwang,6 Ye Soo Park,6 Sun Kyung Oh,4 Hee Sun Kim,4 Jong Hyuk Park,7 Shin Yong Moon,4 Gerald Schatten7*

Patient-specific, immune-matched human embryonic stem cells (hESCs) are anticipated to be of great biomedical importance for studies of disease and development and to advance clinical deliberations regarding stem cell transplantation. Eleven hESC lines were established by somatic cell nuclear transfer (SCNT) of skin cells from patients with disease or injury into donated oocytes. These lines, nuclear transfer (NT)–hESCs, grown on human feeders from the same NT donor or from genetically unrelated individuals, were established at high rates, regardless of NT donor sex or age. NT-hESCs were pluripotent, chromosomally normal, and matched the NT patient's DNA. The major histocompatibility complex identity of each NT-hESC when compared to the patient's own showed immunological compatibility, which is important for eventual transplantation. With the generation of these NT-hESCs, evaluations of genetic and epigenetic stability can be made. Additional work remains to be done regarding the development of reliable directed differentiation and the elimination of remaining animal components. Before clinical use of these cells can occur, preclinical evidence is required to prove that transplantation of differentiated NT-hESCs can be safe, effective, and tolerated.

1 College of Veterinary Medicine, Seoul National University, Seoul 151-742, Korea.
2 School of Agricultural Biotechnology, Seoul National University, Seoul 151-742, Korea.
3 Medical Research Center, MizMedi Hospital, Seoul 135-280, Korea.
4 College of Medicine, Seoul National University, Seoul 110-744, Korea.
5 Hanna Women's Clinic, Seoul 137-872, Korea.
6 School of Medicine, Hanyang University, Seoul 471-701, Korea.
7 Pittsburgh Development Center, Magee-Womens Research Institute, Department of Obstetrics, Gynecology, and Reproductive Sciences and Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

* To whom correspondence should be addressed. E-mail: hwangws{at}snu.ac.kr (W.S.H.); gschatten{at}pdc.magee.edu (G.S.)

Read the Full Text


E-Letters:

Read all E-Letters

Egg-sharing to alleviate the shortage of donor oocytes for therapeutic cloning
Boon C. Heng, et al.
Science Online, 24 May 2005 [Full text]

ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)